LOGIN  |  REGISTER
Assertio
Terns Pharmaceuticals

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer

May 14, 2025 | Last Trade: US$2.99 0.05 -1.64

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the University of Connecticut where he was a practicing oncologist for many years.

“We are ecstatic that Dr. Langsam is joining our already impressive group of clinical leaders at TOI as our next CCO.” said Daniel Virnich, CEO of The Oncology Institute. “As we see acceleration in new value-based partnerships across the country and growth in our MSO model, Dr. Langsam’s deep expertise in Oncology and Specialty Pharmacy will be pivotal in scaling our therapeutic decision-making model across the enterprise and building a high-value engaged MSO network.”

“I couldn’t be more excited about joining the senior leadership team at TOI as CCO”, commented Dr. Langsam. “TOI has been leading value-based community oncology for many years, and acceleration in risk-based contracts and service offerings makes this a critical moment for the organization to continue scaling its clinical model to provide even greater benefits to patients and payor partners.”

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.

For more information, visit www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors

Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page